Chrissie T. Wøien, Thomas M. Andersen, Peter Zvara
New minimally invasive therapies of benign prostatic hyperplasia have been developed during last decades with the
goal to reduce invasiveness, frequency and severity of complications. This communication discusses four minimally invasive
therapies which are most advanced in their development and testing. We describe the individual techniques,
their mechanism of action, advantages and limitations and present available clinical data regarding their safety and efficacy.
Even though the outcomes of many clinical studies are promising, at this point all these methods remain experimental.
Some have shown considerable potential, and it is possible that one or more will be adopted into the broad
clinical practice, however for most, long-term efficacy and safety data still need to be generated.